Capital Markets Tutorial | November 2022:

Bioanalytics | Cell Culture Media | Chromatography

Capital Markets Tutorial: Bioanalytics

Gerry Mackay, Fiona Coats

Lab Products & Services (LPS): premium supplier for Life Science research and quality control labs

~€720mn

Sales revenue 2021

17.6%

Sales CAGR1 2016-2021

26.1%

EBITDA margin2 2021

~50%

Recurring revenue

Portfolio includes lab instruments, consumables, software and services

Bioanalytics

Lab instruments

Lab consumables

1 In constant currencies 2 Excluding extraordinary items

3

Continuous transition to a higher growth and profitability profile for LPS

LPS sales revenue, € in millions; EBITDA margin1 in %

00.0

CAGR2 17.6%

722.2

700.0

26.1

00.0

00.0

00.0

325.3

300.0

16.0

200.0

100.0

2016

2017

2018

2019

2020

2021

30.0

28.0

26.0

24.0

22.0

20.0

18.0

16.0

14.0

Growth drivers

Sales & Marketing pivot to attractive segments and regions

Attractive portfolio mix coupled with M&A

Launch of innovative products

Improved brand awareness

1 Excluding extraordinary items 2 In constant currencies

4

Focus on attractive Life Science market and more balanced regional profile

Sales revenue share by segment, 2021 vs. 2017

2021

Life Science

Applied

research

research

~55% (~42%)

~45% (~58%)

2017

of which

Bioanalytics

>30pp (~14pp)

Sales revenue share by geography, 2021 vs. 2017

2021

Americas

EMEA

~32% (~25%)

~39% (~48%)

2017

Asia|Pacific ~29% (~27%)

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Sartorius AG published this content on 22 November 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 November 2022 08:55:05 UTC.